ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2476

Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)

Pooja Dhaon1, Siddharth K. Das2, Ragini Srivastava3 and Urmila Dhakad4, 1Medicine, Hind Institute of Medical Sciences, Uttar Pradesh, India., Barabanki, India, 2Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, 3Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, 4Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Evaluation, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose : To compare the performance of DAS-28 CRP, CDAI and SDAI composite measures to assess status of patients with Rheumatoid Arthritis on Methotrexate, versus DAS-28 CRP as the gold standard.  

Methods :  135 patients with RA as per the 2010 ACR/EULAR criteria were included in the prospective study. The disease activity was assessed at baseline and at every 6 weeks for 24 weeks, by DAS-28 CRP, CDAI and SDAI. Patients were divided into groups of remission, low, moderate and high activity on the basis of predefined cut-offs for DAS-28 CRP, CDAI, and SDAI. A Spearman correlation between composite measures and inter-group comparison of the measures were performed.

Results : There was an excellent positive correlation between DAS-28 CRP and CDAI (linear weighted k baseline – 0.545), DAS-28 CRP and SDAI (linear weighted k – 0.689) at baseline. There was moderate agreement between DAS-28 CRP and CDAI (linear weighted k final visit – 0.458) at final visit. There was moderate correlation between SDAI and DAS 28 CRP at final visit (linear weighted k– 0.470). (Fig shows excellent correlation between CDAI vs DAS 28 CRP and SDAI vs DAS28 CRP at base line but not at final visit. However, correlation between CDAI vs SDAI remained excellent). Patients in remission as per DAS-28 CRP had significantly more residual disease activity compared to SDAI and CDAI remission criteria.

Conclusion: The study shows an excellent strong positive correlation between DAS-28 CRP, CDAI and SDAI at initial evaluation but not at final visit. SDAI and CDAI based remission criteria seems to be better than DAS28-CRP based remission criteria.  

 


Disclosure: P. Dhaon, None; S. K. Das, None; R. Srivastava, None; U. Dhakad, None.

To cite this abstract in AMA style:

Dhaon P, Das SK, Srivastava R, Dhakad U. Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/performance-of-clinical-disease-activity-index-cdai-and-simplified-disease-activity-index-sdai-appears-to-be-better-than-gold-standard-disease-assessment-score-das-28-crp/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-clinical-disease-activity-index-cdai-and-simplified-disease-activity-index-sdai-appears-to-be-better-than-gold-standard-disease-assessment-score-das-28-crp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology